Cancer Therapy Related Diarrhea – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Cancer Therapy Related Diarrhea – Pipeline Insight, 2020,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Cancer Therapy Related Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cancer Therapy Related Diarrhea: Overview
Cancer Therapy Related Diarrhea is a common problem, especially in patients with advanced cancer. It is one of the main drawbacks for cancer patients. In oncological patients, diarrhea can occur in several different situations. Possible causes could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease and infections and has to be carefully differentiated from other causes of diarrhea. Cancer therapy related diarrhea can cause depletion of fluids and electrolytes, malnutrition, dehydration and hospitalization, all of which can lead to cardiovascular compromise and death. In addition, diarrhea can interfere with and detract from cancer treatment by causing dosing delays or reductions which may have an impact on survival.
Symptoms
The symptoms of Cancer Therapy Related Diarrhea include:
Diagnosis of Cancer Therapy Related Diarrhea begins with a history to determine the severity according to the National Cancer Institute Common Toxicity grades. The volume and duration of diarrhea should also be determined, and the history should include questions concerning foods or drugs that might play a contributory role.
Treatment
The treatment of CID includes nonpharmacologic and pharmacologic interventions to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization. Initial nonpharmacologic measures include avoidance of foods that would aggravate the diarrhea and aggressive oral rehydration with fluids that contain water, salt, and sugar. loperamide, octreotide and tincture of opium are recommended in the updated treatment guidelines by the consensus conference on the management of Cancer Therapy Related Diarrhea.
Cancer Therapy Related Diarrhea Emerging Drugs Chapters
This segment of the Cancer Therapy Related Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cancer Therapy Related Diarrhea Emerging Drugs
Further product details are provided in the report
Cancer Therapy Related Diarrhea: Therapeutic Assessment
This segment of the report provides insights about the different Cancer Therapy Related Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:
Cancer Therapy Related Diarrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Therapy Related Diarrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Therapy Related Diarrhea drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cancer Therapy Related Diarrhea – Pipeline Insight, 2020,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Cancer Therapy Related Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cancer Therapy Related Diarrhea: Overview
Cancer Therapy Related Diarrhea is a common problem, especially in patients with advanced cancer. It is one of the main drawbacks for cancer patients. In oncological patients, diarrhea can occur in several different situations. Possible causes could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease and infections and has to be carefully differentiated from other causes of diarrhea. Cancer therapy related diarrhea can cause depletion of fluids and electrolytes, malnutrition, dehydration and hospitalization, all of which can lead to cardiovascular compromise and death. In addition, diarrhea can interfere with and detract from cancer treatment by causing dosing delays or reductions which may have an impact on survival.
Symptoms
The symptoms of Cancer Therapy Related Diarrhea include:
- Dehydration
- Dizzy or light headed
- Fever
- Dark yellow urine or not urinating
Diagnosis of Cancer Therapy Related Diarrhea begins with a history to determine the severity according to the National Cancer Institute Common Toxicity grades. The volume and duration of diarrhea should also be determined, and the history should include questions concerning foods or drugs that might play a contributory role.
Treatment
The treatment of CID includes nonpharmacologic and pharmacologic interventions to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization. Initial nonpharmacologic measures include avoidance of foods that would aggravate the diarrhea and aggressive oral rehydration with fluids that contain water, salt, and sugar. loperamide, octreotide and tincture of opium are recommended in the updated treatment guidelines by the consensus conference on the management of Cancer Therapy Related Diarrhea.
Cancer Therapy Related Diarrhea Emerging Drugs Chapters
This segment of the Cancer Therapy Related Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cancer Therapy Related Diarrhea Emerging Drugs
- Crofelemer: Napo Pharmaceuticals
Further product details are provided in the report
Cancer Therapy Related Diarrhea: Therapeutic Assessment
This segment of the report provides insights about the different Cancer Therapy Related Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cancer Therapy Related Diarrhea
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cancer Therapy Related Diarrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Therapy Related Diarrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Therapy Related Diarrhea drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Therapy Related Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Therapy Related Diarrhea.
- Cancer Therapy Related Diarrhea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cancer Therapy Related Diarrhea drugs?
- How many Cancer Therapy Related Diarrhea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Therapy Related Diarrhea?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cancer Therapy Related Diarrhea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cancer Therapy Related Diarrhea and their status?
- What are the key designations that have been granted to the emerging drugs?
- Napo Pharmaceuticals
- Crofelemer
Introduction
Executive Summary
Cancer Therapy Related Diarrhea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cancer Therapy Related Diarrhea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cancer Therapy Related Diarrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cancer Therapy Related Diarrhea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Crofelemer: Napo Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Cancer Therapy Related Diarrhea Key Companies
Cancer Therapy Related Diarrhea Key Products
Cancer Therapy Related Diarrhea- Unmet Needs
Cancer Therapy Related Diarrhea- Market Drivers and Barriers
Cancer Therapy Related Diarrhea- Future Perspectives and Conclusion
Cancer Therapy Related Diarrhea Analyst Views
Cancer Therapy Related Diarrhea Key Companies
Appendix
Executive Summary
Cancer Therapy Related Diarrhea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cancer Therapy Related Diarrhea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cancer Therapy Related Diarrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cancer Therapy Related Diarrhea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Crofelemer: Napo Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Cancer Therapy Related Diarrhea Key Companies
Cancer Therapy Related Diarrhea Key Products
Cancer Therapy Related Diarrhea- Unmet Needs
Cancer Therapy Related Diarrhea- Market Drivers and Barriers
Cancer Therapy Related Diarrhea- Future Perspectives and Conclusion
Cancer Therapy Related Diarrhea Analyst Views
Cancer Therapy Related Diarrhea Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cancer Therapy Related Diarrhea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cancer Therapy Related Diarrhea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cancer Therapy Related Diarrhea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cancer Therapy Related Diarrhea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
